CRISPR Therapeutics AG (CRSP – Free Report) closed the latest trading day at $41.22, indicating a +0.12% change from the previous session’s end. This change outpaced the S&P 500’s 0.08% gain on the day. On the other hand, the Dow registered a gain of 0.08%, and the technology-centric Nasdaq increased by 0.52%.
The company’s stock has dropped by 18.36% in the past month, falling short of the Medical sector’s loss of 1.03% and the S&P 500’s loss of 7.33%.
The investment community will be closely monitoring the performance of CRISPR Therapeutics AG in its forthcoming earnings report. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.31 per share, which would represent year-over-year growth of 8.39%. Our most recent consensus estimate is calling for quarterly revenue of $5.21 million, up 942% from the year-ago period.
CRSP’s full-year Zacks Consensus Estimates are calling for earnings of -$5.13 per share and revenue of $55.61 million. These results would represent year-over-year changes of -18.2% and +49.04%, respectively.
It is also important to note the recent changes to analyst estimates for CRISPR Therapeutics AG. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company’s business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 1.9% lower. At present, CRISPR Therapeutics AG boasts a Zacks Rank of #3 (Hold).
The Medical – Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 75, which puts it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Financial Market Newsflash
No financial news published today. Check back later.
